ARIX:LSE-Arix Bioscience PLC (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 110.00

Change

0.00 (0.00)%

Market Cap

GBX 0.14B

Volume

0.15M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ARIX Stock Forecast & Price:
Based on the Arix Bioscience PLC stock forecasts from 0 analysts, the average analyst target price for Arix Bioscience PLC is not available over the next 12 months. Arix Bioscience PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arix Bioscience PLC is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Arix Bioscience PLC’s stock price was GBX 110.00. Arix Bioscience PLC’s stock price has changed by -2.65% over the past week, -5.98% over the past month and -30.38% over the last year.

No recent analyst target price found for Arix Bioscience PLC
No recent average analyst rating found for Arix Bioscience PLC

About Arix Bioscience PLC (ARIX:LSE)

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biote ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABC:LSE Abcam plc

+13.00 (+0.97%)

GBX3.02B 220.00 66.30
ONT:LSE Oxford Nanopore Technologies L..

-1.00 (-0.42%)

GBX2.03B N/A -12.14
GNS:LSE Genus PLC

-64.00 (-2.43%)

GBX1.80B 44.03 21.91
PRTC:LSE PureTech Health plc

-2.00 (-0.93%)

GBX0.62B 225.00 -40.45
ERGO:LSE Ergomed Plc

-12.00 (-1.04%)

GBX0.57B 45.44 28.00
SLN:LSE Silence Therapeutics plc

N/A

GBX0.48B N/A N/A
OXB:LSE Oxford BioMedica PLC

+5.00 (+1.35%)

GBX0.36B 18.55 -695.86
AVCT:LSE Avacta Group PLC

+1.00 (+0.98%)

GBX0.26B N/A -8.74
VRP:LSE Verona Pharma plc

N/A

GBX0.23B N/A N/A
REDX:LSE Redx Pharma Plc

N/A

GBX0.19B N/A -11.24

ETFs Containing ARIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.09% 89% B+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.09% 89% B+ 68% D+
Trailing 12 Months  
Capital Gain -29.26% 75% C 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.26% 75% C 33% F
Trailing 5 Years  
Capital Gain -45.14% 45% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.14% 45% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 2.38% 30% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.38% 30% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 62.09% 55% F 15% F
Risk Adjusted Return 3.84% 30% F 45% F
Market Capitalization 0.14B 81% B- 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.15 75% C 53% F
Price/Book Ratio 0.63 93% A 83% B
Price / Cash Flow Ratio -19.91 83% B 92% A-
EV/EBITDA -2.67 45% F 75% C
Management Effectiveness  
Return on Equity -20.71% 74% C 13% F
Return on Invested Capital -20.61% 76% C 9% F
Return on Assets -13.51% 72% C- 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.26 32% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.